NANOCOMPOSIX, INC. — Department of Defense SBIR Phase I: DHP16-006
NANOCOMPOSIX, INC. — SBIR Phase I award from Department of Defense.
- Amount
- $150,000
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase I
- Topic
- DHP16-006
- Solicitation
- 2016.1
- NAICS
- —
- Place of performance
- CA
- Period
- 2016-09-26 → 2017-03-25
Description
Combat soldiers are exposed to vast numbers of dangerous chemicals with potentially adverse health outcomes.This SBIR proposal aims to develop a new class of saliva based diagnostic assays that will measure the bodys response to toxic chemical exposure via a panel of clinically used biomarkers that are indicative of organ injury.The tests will leverage the proven functionality of lateral flow diagnostic devices with novel nanoparticles and extraction formats that have the potential to increase lateral flow assay sensitivity by up to 3 orders of magnitude over the current state of the art.A cardiac troponin I salivary diagnostic will be developed as a proof of concept organ damage marker.The developed diagnostic will be rapid, inexpensive and accurate.A smartphone reader will quantify the signal from each of the channels of the multiplexed diagnostic, geotag the data and interpret the results.